<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638881</url>
  </required_header>
  <id_info>
    <org_study_id>58859</org_study_id>
    <nct_id>NCT04638881</nct_id>
  </id_info>
  <brief_title>Magnesium for Peroral Endoscopic Myotomy</brief_title>
  <acronym>MgPOEM</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled Trial of the Effects of Magnesium Sulfate on Postoperative Esophageal Spasm-associated Pain Following Peroral Endoscopic Myotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal&#xD;
      smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant.&#xD;
      This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will&#xD;
      reduce the incidence of postoperative pain while decreasing perioperative opioid&#xD;
      requirements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Esophageal Symptoms Questionnaire Score (ESQ)</measure>
    <time_frame>0 hours postoperatively</time_frame>
    <description>ESQ score is a validated survey score based on questions evaluating esophageal dysphagia, globus, and reflux. Responses based on a scale of 1 (Not severe) to 7 (Very severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophageal Symptoms Questionnaire Score (ESQ)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>ESQ score is a validated survey score based on questions evaluating esophageal dysphagia, globus, and reflux. Responses based on a scale of 1 (Not severe) to 7 (Very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid usage</measure>
    <time_frame>Between induction of anesthesia and up to 5 minutes after extubation (total estimated time frame 2 hours)</time_frame>
    <description>Measured in intravenous fentanyl equivalents and oral morphine milliequivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total postoperative opioid consumption</measure>
    <time_frame>From extubation to 24 hours after extubation</time_frame>
    <description>Measured in intravenous fentanyl equivalents and oral morphine milliequivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge opioid prescriptions</measure>
    <time_frame>At time of discharge (up to 1 minute)</time_frame>
    <description>Measured in intravenous fentanyl equivalents and oral morphine milliequivalents</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esophageal Spasm</condition>
  <arm_group>
    <arm_group_label>Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.</description>
    <arm_group_label>Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo. Bolus and infusion administered similarly under general anesthesia.</description>
    <arm_group_label>Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Planned peroral endoscopic myotomy procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cannot give consent&#xD;
&#xD;
          -  patients who are clinically unstable and/or require urgent/emergent intervention&#xD;
&#xD;
          -  previous esophageal myotomy&#xD;
&#xD;
          -  preexisting hypermagnesemia&#xD;
&#xD;
          -  end-stage renal disease&#xD;
&#xD;
          -  neuromuscular disease, including but not limited to Guillain-Barre syndrome,&#xD;
             myasthenia gravis, congenital myopathy, and muscular dystrophy&#xD;
&#xD;
          -  preexisting heart failure&#xD;
&#xD;
          -  severe ventricular systolic dysfunction (left or right ventricle)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo H Hwang, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ban C Tsui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard K Kim, MD</last_name>
    <phone>347-586-9661</phone>
    <email>rkwkim@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ban Tsui, MD</last_name>
      <phone>650-200-9107</phone>
      <email>bantsui@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chynna Villanueva, BS, RN</last_name>
      <phone>(650) 498-6346</phone>
      <email>chynnav@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Chi-Ho Ban Tsui</investigator_full_name>
    <investigator_title>Professor-Med Ctr Line</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Spasm, Diffuse</mesh_term>
    <mesh_term>Esophageal Motility Disorders</mesh_term>
    <mesh_term>Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

